Cuorips, Inc. engages in the development and commercialization of induced pluripotent stem cells (iPS) derived cardiomyocyte sheets. It handles research, development, manufacture, and sales of cellular and tissue-based products and cell processing products. The firm also offers contract development and manufacturing services and consulting services of cellular and tissue-based products and cell processing products. The company was founded on March 21, 2017 and is headquartered in Tokyo, Japan.